Medyssey's posterior lumbar interbody fusion system gets 510(k) clearance
This article was originally published in Clinica
Executive Summary
The LP Cage spinal implant developed by Korean company Medyssey Spine has received 510(k) clearance from the US FDA. The device is indicated for use in lumbar interbody fusion procedures in skeletally mature patients with degenerative disc disease at one or two contiguous levels from L2-S1 vertebrae in the lower spine. It is currently undergoing a limited market release; full commercial launch is planned for the fourth quarter of 2011. The Seoul-based company also announced an 84% increase in US sales in the first quarter of 2011 over the same period in 2010. It says it is on course to achieve its eighth consecutive year of market share growth in the global spine market.
You may also be interested in...
Falling Sales Force New Priorities At Roche
The Swiss major brings a new ruthlessness to the compounds in its pipeline: if they’re not first or best, they’re out.
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.
Normality Reasserts Itself For Biotech IPOs
The highs of the COVID-19 era, and the lows that supplanted it, are beginning to fade.